Epigenetics Global Market Report 2024

Epigenetics refers to changes in gene activity transmitted to younger cells without modifying the DNA sequence. These natural and necessary processes are vital for the functioning of many organisms, but anomalies can lead to disorders such as various types of cancer, reproductive illnesses, and cardiovascular diseases. Epigenetics plays a crucial role in the early detection of certain cancers.

The primary products employed in the epigenetics market include reagents, enzymes, instruments, and kits. Reagents are compounds or substances used for chemical analysis or epigenetic testing. Technologies utilized in epigenetics encompass DNA methylation, histone methylation, histone acetylation, large noncoding RNA, microRNA modification, and chromatin structures. Applications span oncology, metabolic diseases, developmental biology, immunology, cardiovascular diseases, and other fields. Epigenetic tools find applications in academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations, and various other end-user segments.

The epigenetics market research report is one of a series of new reports that provides epigenetics market statistics, including epigenetics industry global market size, regional shares, competitors with an epigenetics market share, detailed epigenetics market segments, market trends and opportunities, and any further data you may need to thrive in the epigenetics industry. This epigenetics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The epigenetics market size has grown exponentially in recent years. It will grow from $9 billion in 2023 to $10.91 billion in 2024 at a compound annual growth rate (CAGR) of 21.2%. The growth in the historic period can be attributed to increased research funding, a rise in the incidence of chronic diseases, the emergence of personalized medicine, extensive research in cancer, and an aging population.

The epigenetics market size is expected to see exponential growth in the next few years. It will grow to $23.86 billion in 2028 at a compound annual growth rate (CAGR) of 21.6%. The growth in the forecast period can be attributed to developments in epigenetic drug development, increased focus on epigenetics in environmental health, applications of epigenetics in precision agriculture, regulatory support, and growing awareness and advocacy among patients. Major trends in the forecast period include advancements in epitranscriptomics, single-cell epigenomics, the emergence of epigenetic editing, utilization of epigenetic biomarkers, increased research in aging and longevity, and exploration of microbiome-epigenome interactions.

The growth of the epigenetics market is significantly influenced by the increasing prevalence of cancer and other diseases. The rising incidence of diseases, such as cancer, drives the demand for epigenetic testing and analysis. For instance, a report from the European Commission's Joint Research Centre in September 2021 projected a 21.4% increase in new cancer cases in the European Union and European Free Trade Association countries from 2.8 million in 2020 to 3.4 million in 2040. Additionally, data from the Centers for Disease Control and Prevention (CDC) indicated that approximately 659,000 people in the United States die from heart disease each year. The need for understanding genetic modifications in diseases like cancer enhances the usage and demand for epigenetics. Consequently, the growing prevalence of cancer and other diseases is a major driver fueling the epigenetics market.

The epigenetics market is expected to experience growth due to the increasing focus on precision medicine. Precision medicine involves tailoring medical approaches based on an individual's genetic, environmental, and lifestyle information for more effective disease management and treatment. In the realm of epigenetics, precision medicine utilizes individual epigenetic profiles and genetic data to formulate personalized healthcare strategies. In 2022, the Food and Drug Administration's Center for Drug Evaluation and Research approved 37 new molecular entities, with 34% of therapeutic new molecular entities classified as personalized medicines, according to the Personalized Medicine Coalition. This emphasis on precision medicine is contributing to the expansion of the epigenetics market.

A key trend in the epigenetics market is technological advancement. Major players in the epigenetics sector are dedicated to developing advanced products and services, leveraging cutting-edge technologies to enhance their market positions. For instance, Givaudan Active Beauty, a Switzerland-based company, launched Chronoglow in May 2021. Chronoglow is a skin-care-beneficial active component created through green fractionation and supported by artificial intelligence (AI). It replicates natural epigenetic mechanisms and is derived from the resurrection plant, Haberlea rhodopensis. Chronoglow acts as a natural skin remedy, improving skin luminosity and reversing signs of aging. The trend of technological advancement is shaping the landscape of the epigenetics market.

Leading companies in the epigenetics market are increasingly incorporating artificial intelligence (AI)-driven analytics into their operations to gain a competitive advantage. AI-driven analytics involves utilizing artificial intelligence technologies to automatically analyze and interpret large volumes of data. For example, in July 2023, FOXO Technologies, a US-based company, introduced Bioinformatics Services aimed at revolutionizing epigenetic data analysis. These services offer a versatile platform with advanced data solutions tailored to meet the specific needs of clients in academia, healthcare, and pharmaceutical research. FOXO's innovative suite of bioinformatic tools aims to enhance the speed and accuracy of data processing, analysis, and interpretation, facilitating quicker discoveries and advancing understanding of complex diseases.

In a strategic move, Chroma Medicine Inc., a prominent biotechnology company based in the United States, acquired Epsilen Bio for $125 billion in November 2021. This acquisition is expected to play a crucial role in expanding Chroma Medicine Inc.'s epigenetic editing platform and reinforcing its position in the market. Epsilen Bio, headquartered in Italy, specializes in developing transformative therapies through targeted epigenetic silencing of genes. This acquisition aligns with the broader industry trend of companies investing in technologies and capabilities to drive advancements in the field of epigenetics.

Major companies operating in the epigenetics market include Illumina Inc., Thermo Fisher Scientific, Merck Millipore, Abcam, Active Motif, Abcam PLC, Active Motiff, Hologic Inc., Qiagen NV, Diagenode SA, CellCentric Ltd., Chroma Medicine Inc., Constellation Pharmaceuticals Inc., Cytosine Therapeutics, Domainex Ltd., Eisai Co. Ltd., Epigen Biosciences Inc., EpigenDx Inc., Epigenomics AG, Epizyme Inc., Gilead Sciences Inc., GlaxoSmithKline PLC, Janssen Pharmaceuticals Inc., Locus Biosciences Inc., MDxHealth SA, Novartis AG, OncoDNA SA, Oryzon Genomics S.A., Pfizer Inc., Syndax Pharmaceuticals Inc., Valirx PLC, Zymeworks Inc.

North America was the largest region in the epigenetics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the epigenetics market during the forecast period. The regions covered in the global epigenetics market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the epigenetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The epigenetics market includes revenues earned by entities methylation, acetylation, phosphorylation, ubiquitylation, and sumolyation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.